University of Kentucky College of Medicine Hematology and Medical Oncology

Topics

• Cutaneous lymphoproliferative disorders research 83
• Neuroendocrine Tumor Research Advances 80
• Lymphoma Diagnosis and Treatment 74
• Glioma Diagnosis and Treatment 50
• Acute Myeloid Leukemia Research 45
• Cancer Immunotherapy and Biomarkers 26
• Chronic Lymphocytic Leukemia Research 24
• Lung Cancer Treatments and Mutations 22
• Bladder and Urothelial Cancer Treatments 20
• Head and Neck Cancer Studies 20
• CAR-T cell therapy research 19
• Hematopoietic Stem Cell Transplantation 19

Most cited

1. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.

   JAMA oncology · 2023 · 399 citations · John Villano

2. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.

   The New England journal of medicine · 2024 · 205 citations · Hayder Saeed

3. Immunotherapy in Breast Cancer.

   International journal of molecular sciences · 2024 · 134 citations · Kathrin Dvir

4. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 175 citations · John Villano

5. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.

   Blood · 2021 · 295 citations · Dianna Howard

6. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.

   JAMA · 2023 · 126 citations · John Villano

7. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 130 citations · Firas Badin

8. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.

   The Lancet. Oncology · 2022 · 226 citations · Susanne Arnold